Trainee Pearls
Avsnitt

#16 Aina Oliver-Caldés: Academic CAR-T cells for myeloma

Trainee Pearls
Dela

Chimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments worldwide. Aina and colleagues assessed the safety and activity of ARI0002h, a BCMA-targeted CAR T-cell therapy developed by academia, in patients with relapsed or refractory multiple myeloma. https://pubmed.ncbi.nlm.nih.gov/37414060/

ALSO AS VIDEO ON https://youtu.be/Ymgg22roWGU

CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee https://twitter.com/CarmeloGurnari


Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör The EBMT Trainee Committee. Innehållet i podden är skapat av The EBMT Trainee Committee och inte av, eller tillsammans med, Poddtoppen.